Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Response for airborne Pathogen On-chip Diagnostics

Project description

Rapid on-site detection of airborne antibiotic-resistant pathogens

Hospital air can carry antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Acinetobacter baumannii (CRAB), contributing to healthcare-associated infections and the spread of antimicrobial resistance. While current air management methods reduce particles, they do not confirm the presence of viable pathogens. Supported by the Marie Skłodowska-Curie Actions programme, the RESPOND project will develop a microfluidic platform for the rapid detection of airborne pathogens. It will combine plasmonic-enhanced bacterial lysis, isothermal nucleic acid amplification and photoelectrochemical biosensing into a single chip. Key features include reagent-free lysis, optics-free detection and a quick turnaround time of under 60 minutes, with a limit of detection of approximately 10 copies per microlitre and a cost of under EUR 50 per chip.

Objective

Hospital air is rarely as clean as it appears. In intensive care units, operating theatres, and patient wards, airborne pathogens such as Staphylococcus aureus (MRSA) and Acinetobacter baumannii persist as silent, mobile threats, exacerbating the burden of antimicrobial resistance (AMR) and hospital-acquired infections. Current air-management strategies—ventilation, HEPA filtration, UV-C sterilisation, and negative-pressure rooms—reduce particle loads but cannot confirm the presence of viable pathogens. Fluorescence-based particle counters provide only generic biological activity, while culture and molecular diagnostics are too slow, infrastructure-dependent, and unsuitable for real-time intervention. This blind spot leaves healthcare settings unprepared to respond effectively to airborne outbreaks. RESPOND project addresses this gap by developing an integrated, microfluidic platform combining plasmonic-enhanced bacterial lysis, isothermal nucleic acid amplification, and photoelectrochemical (PEC) biosensing. Module 1, engineered plasmonic nanostructures (gold nanostars, silver nanocubes) under LED illumination will achieve rapid, reagent-free lysis of bacteria, preserving nucleic acids for downstream amplification. Module 2, solid-phase recombinase polymerase amplification will be coupled with wavelength-selective photosensitisers for PEC detection, enabling label-free, light-controlled readouts without bulky optics. Module 3 will integrate both units into a continuous-flow microfluidic chip, validated with airborne MRSA and A. baumannii under clinically relevant conditions. Scientifically, RESPOND goes beyond state-of-the-art by embedding reagent-free lysis and optics-free PEC sensing in a chip, enabling rapid, species-specific airborne pathogen detection (<60 minutes, LOD ≈10copies/µL, cost per-chip <€50). Societally, RESPOND enhances hospital resilience against AMR outbreaks, supports real-time infection control, scalable applications in healthcare.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSITEIT ANTWERPEN
Net EU contribution
€ 200 400,00
Address
PRINSSTRAAT 13
2000 Antwerpen
Belgium
Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data